NCT01296035View on ClinicalTrials.gov

Panitumumab and Gemcitabine in Relapsed Ovarian Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

February 28, 2011

Primary Completion Date

October 31, 2013

Study Completion Date

November 30, 2013

Conditions
Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
Interventions
BIOLOGICAL

Panitumumab

Panitumumab 2.5 mg/kg on D1, D8, D15, and D22 and Gemcitabine 800 mg/m2 on D1, D8, and D15 of each 28 day cycle.

Trial Locations (1)

02905

Women & Infants' Hospital, Providence

Sponsors

Collaborators (1)

Amgen
All Listed Sponsors
collaborator

Amgen

INDUSTRY

lead

Women and Infants Hospital of Rhode Island

OTHER